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In human cancer, DNA hypermethylation is known to occur in
CpG islands, which are 1- to 2-kb GC-rich regions frequently
located within the 5¢ ends of about 60% of all genes (Laird and
Jaenisch, 1994). This type of epigenetic mutation has been shown
to be associated with transcriptional silencing of tumour
suppressor genes in neoplasia (Baylin et al, 1997). The abnormal
event is generally accepted as a stochastic process in tumour cells
with a hypermethylator phenotype (Pfeifer et al, 1990; Jones,
1996; Huang et al, 1999). The random process may occur at CpG
sites within the 5¢ regulatory regions of critical tumour suppressor
genes. The resulting progressive silencing of transcription can
provide these cells with a greater proliferative advantage (Jones,
1996). In addition to classical genetic mutations, DNA hyper-
methylation plays a significant role in promoting tumorigenesis.
Abundant ribosomal DNA shares some characteristics with
single-copy CpG islands. The entire 13.3-kb transcriptional
domain of ribosomal DNA (rDNA) is GC-rich, but is much longer
than a typical 1- to 2-kb CpG island (Worton et al, 1988). In
normal human cells, the rDNA transcribed domain is predomi-
nately unmethylated, and has been associated with active tran-
scription of 18S, 5.8S and 28S RNA subunits (Dante et al, 1992;
Gonzalez et al, 1992). Juxtaposed to the 3¢ end of the transcribed
domain is a low GC-containing non-transcribed spacer (30-kb)
known to contain methylated CpG sites (Brock and Bird, 1997).
Approximately 400 copies of rDNA per haploid genome are
located on the short arms of human acrocentric chromosomes
(Worton et al, 1988). These repeat units are arranged in head-to-
tail arrays with each chromosome cluster containing approxi-
mately 80 copies (Sakai et al, 1995).
Since both rDNA and CpG islands share similar properties, we
sought to determine whether rDNA is subject to aberrant methyla-
tion in breast cancer. Methylation analysis was performed by
Southern hybridization using the entire transcribed region as a
probe in a group of patients with infiltrating ductal carcinomas.
The resulting rDNA methylation data were used to examine their
association with patients’ clinicopathological parameters.
PATIENTS AND METHODS
Patients and samples
Breast tumour specimens were obtained from 58 patients under-
going partial or complete mastectomies at the Ellis Fischel Cancer
Center (Columbia, MO, USA). Specimen collection and tissue
analyses were approved by the Institutional Review Board of the
University of Missouri Health Science Center. Clinicopathological
parameters and TNM (Tumour-Nodal-Metastasis) classification
were performed using standard criteria (Beahrs, 1989). All
tumours were classified as infiltrating ductal carcinomas. The
oestrogen receptor (ER) and progesterone receptor (PR) status 
of tumour tissues was determined by either the dextran-coated
charcoal assay (negativity defined as ≤ 3 fmol mg–1 ligand bound
protein) or the immunoperoxidase technique (negativity defined as
≤ 20% of tumour nuclei stained positive). Non-neoplastic breast
tissue was also obtained from ten study subjects and used as
‘normal controls’. High-molecular-weight DNA was isolated
using the QIAamp Tissue KitTM (Qiagen Inc, Chatsworth, CA,
USA).
Methylation analysis by Southern hybridization
Genomic DNA (approximately 2.5 mg) from breast tissues was
digested to completion with methylation-sensitive HpaII (cuts
C¯CGG, but not CmCGG; m: methylated) or its methylation-
insensitive isoschizomer MspI (cuts both C¯CGG and C¯mCGG).
The restriction products were separated on 1.0% agarose gels and
transferred to nylon membranes. The membranes were hybridized
with 32P-labelled pHsrDNA5.1 and pHsrDNA7.9 probes (Figure
1A) at 70°C in 10 ml of High Efficiency Hybridization solution
(Molecular Research, Inc., Cincinnati, OH, USA). Probes were
radiolabelled using the Multiprime DNA Labelling System
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(Amersham-Pharmacia Biotech, Piscataway, NJ, USA). Washing
was performed once for 20 min in 0.1% sodium dodecyl sulphate
(SDS)–0.5´ SSC (1´ SSC is 0.15 M sodium chloride and 0.015 M
sodium citrate, pH 7.0) and thrice for 20 min each in 0.1%
SDS–0.2´ SSC at 70°C. The hybridized membranes were
subjected to image analysis with a Molecular Dynamics
PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA).
Band intensities were quantified using the densitometric function
of the ImageQuant software (Molecular Dynamics). Methylation
was expressed as the percentage of the intensity of the methylated
fragments to the combined intensities of all the fragments in HpaII
sample lanes as depicted in Figure 1B.
Statistical analyses
The percent rDNA methylation values and the patient ages were
reported as mean ± standard deviation (s.d.). The association
between percent rDNA hypermethylation data and patients’ 
clinicopathological data were analysed using the SAS procedure
PROC TTEST for comparisons having two variables and PROC
GLM for comparisons having three or more variables (Release
6.12, SAS Institute, Cary, NC, USA). Statistical significance was
established as P < 0.05.
RESULTS
Methylation analysis was conducted by Southern hybridization in
58 primary breast tumours and ten normal controls using probes
spanning the transcribed domain of rDNA (Figure 1A). A total of
280 HpaII/MspI sites located within this region were examined.
Representative results are shown in Figure 1B. In control samples,
the pattern (fragments with size < 1 kb) of methylation-sensitive
HpaII restriction was largely the same as that of methylation-
insensitive MspI restriction, indicating that the majority of these
sites within the transcribed domain were unmethylated. Some
fainter fragments appeared as smears (> 1 kb) in the HpaII-
restricted lanes, suggesting a minor proportion of these sites were
methylated and protected from restriction, consistent with a
previous observation in normal cells (Brock and Bird, 1997). In
tumour samples, the patterns between methylation-sensitive and 
-insensitive restrictions were often different. The predominant
fragments of the HpaII-restricted fragments shifted into regions of
higher molecular weights (> 1 kb); a smear of varying length and
band intensity was seen in these regions due to the differing
degrees of methylation in tumour samples. The MspI-digested
fragments in tumours remained essentially similar to those of the
normal control samples.
Table 1 Clinicopathological features of patients with infiltrating ductal carcinoma of the breast.
%rDNA
Patient characteristics n Age methylation P-valuea
(mean ± SD) (mean ± SD)
Normal vs. tumour
Normal breast tissue 10 57.9 ± 15.2 41.0 ± 10.2 0.0001
Tumour breast tissue 58 58.4 ± 15.7 62.4 ± 14.4
Age at diagnosis (years)
<50 20 41.8 ± 4.5 67.1 ± 13.5 NS (0.0743)
³50 38 67.2 ± 11.8 60.0 ± 14.4
Oestrogen receptor (ER)
Positive 31 64.1 ± 15.7 58.5 ± 16.0 0.0273
Negative 27 51.8 ± 13.0 67.0 ± 10.8
Progesterone receptor (PR)
Positive 20 63.8 ± 16.4 59.5 ± 14.9 NS (0.1430)
Negative 34 54.9 ± 14.3 65.5 ± 13.8
Combined ER/PR status
ER+/PR+ 22 64.4 ± 16.5 59.0 ± 15.1 NS (0.0848)
ER+/PR– 9 63.4 ± 14.4 57.2 ± 19.0
ER–/PR– 26 51.9 ± 13.3 66.9 ± 10.0
Mitotic frequency
<20 HPFb 37 60.7 ± 16.6 61.4 ± 13.8 NS (0.1104)
³20 HPF 15 52.0 ± 13.8 68.2 ± 13.6
Tumour differentiation
In all the tumor tissues
WDc 3 76.0 ± 17.3 49.2 ± 18.3 0.0475
MD/PD 50 56.8 ± 15.0 64.8 ± 12.7
In ER+/PR+ subgroup
WD/MD 16 65.8 ± 16.1 57.4 ± 13.8 0.0376
PD 4 59.5 ± 17.9 73.8 ± 8.70
In ER–/PR– subgroup
MD 12 54.0 ± 14.7 68.2 ± 7.1 NS (0.5828)
PD 14 50.1 ± 12.2 65.7 ± 13.6
TNM classificationd
I 9 63.4 ± 14.6 62.6 ± 14.7 NS (0.4966)
II 28 58.6 ± 15.3 63.7 ± 13.5
III 7 52.0 ± 10.9 61.5 ± 16.5
IV 5 51.6 ± 18.7 73.2 ± 9.30
aStatistical analyses performed on the rDNA methylation values vs. patient characteristics using PROC TTEST or PROC GLM (SAS System, Cary, NC).
Statistically significant (P < 0.05). NS, not significant. bHPF, high power field, 403. cWD, well differentiated; MD, moderately differentiated; PD, poorly
differentiated. All the WD were in the ER+/PR+ subgroup. dClassification according to the TNM system (Beahrs, 1989).rDNA hypermethylation in breast cancer 517
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The resulting methylation data and patients’ clinicopathological
features are summarized in Table 1. An overall increase of rDNA
methylation was seen in ~80% of the breast tumours examined.
The mean percent methylation of breast tumours was significantly
higher than that of normal breast tissue samples (P < 0.0001). The
percent rDNA methylation was also significantly higher in
ER-negative tumours than in ER-positive tumours (P < 0.0273),
and in moderately or poorly differentiated tumours in comparison
to well-differentiated tumours (P < 0.0475). As we further sub-
divided groups by ER and PR combined expression, the poorly
differentiated tumours had significantly higher rDNA methylation
than the moderately or well differentiated tumours within the
ER-positive and PR-positive subgroup (P < 0.0376). rDNA
methylation was essentially the same between moderately and
poorly differentiated tumours in the ER-negative and PR-negative
subgroup (P < 0.5828; none of the well differentiated tumours
belonged to this subgroup). When the diagnosed age of 50 years
old was used as the cutoff, tumours from younger patients (≤ 50
years old) had higher rDNA methylation though the observed
differences were of borderline statistical significance (P-value of
0.0743). Interestingly, this inverse association between age at
diagnosis and rDNA methylation was observed in most of the
tumour subgroups as shown in the ‘Age’ and ‘% rDNA methyla-
tion’ columns in Table 1. The percent rDNA methylation was not
associated with tumour TNM classifications, PR negativity, or
tumour mitotic frequency.
DISCUSSION
This study presents evidence that, in addition to single-copy CpG
islands, abundant rDNA sequences are another type of methyla-
tion substrate in breast cancer. Our data indicated that increased
rDNA methylation was often found in subgroups of patients with
tumour undifferentiation and with younger diagnosed age (≤ 50
years old). Interestingly, rDNA hypermethylation was also corre-
lated with ER negativity (P < 0.0273). Previous studies have
shown that hypermethylation of the ER CpG island was associated
with the lack of ER expression in ER-negative breast cancer cells
(Ottaviano et al, 1994) and in 25% of ER-negative tumours
(Lapidus et al, 1996). These studies also indicated that methylation
silencing of the ER gene might be a primary cause responsible for
some breast cancer patients subsequently becoming insensitive to
anti-oestrogen therapies. Together with these previous results, we
hypothesize that hypermethylation of rDNA and the ER CpG
island can be a related event in breast cancer. If this assumption
were further proven, then the finding could support a generalized
mechanism governing the epigenetic event. Since DNA hyper-
methylation may arise as a stochastic process in tumour cells as
indicated earlier, abundant copies of rDNA can be more available
than single-copy CpG islands in this chance event.
We, therefore, reason that rDNA is a potential marker for
tumours having a greater propensity to methylate their genome
(i.e. hypermethylator phenotype). In the aforementioned clinical
correlation, the random methylation process can simultaneously
occur in both rDNA and the ER CpG island in this subgroup of
breast tumours. In other breast tumours with a hypermethylator
phenotype, aberrant methylation may have already occurred in
abundant rDNA, but not yet in the ER CpG island. Thus, can the
status of hypermethylated rDNA predict this type of tumour
having a high likelihood of developing an ER-negative phenotype
due to subsequent hypermethylation of the ER CpG island? Future
methylation studies of rDNA together with ER and other gene
CpG islands in breast cancer are needed to address this question.
In conclusion, we have shown for the first time that rDNA
hypermethylation occurs in breast tumours, and may be an impor-
tant marker for this epigenetic event in neoplasia. Our finding
highlights the need for further investigations of rDNA hyper-
methylation and its relationship to the development of breast
carcinoma.
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